[Clinical trial of China-made carboplatin in advanced ovarian cancer--an analysis of 53 cases].
Fifty three patients with evaluatable ovarian cancer were conducted a clinical trial of a new antineoplastic drug, carboplatin (cp) made in China. Apart from 1 case of stage Ic and 3 cases of stage II, all the remainders had advanced disease including stage III, IV or recurrences, and mainly consisting of epithelial carcinoma (44 cases). Thirty two patients were treated with single cp at the dose of 260-410 mg/m2 and twenty one were treated with combination chemotherapy of cp at a dose of 180-350 mg/m2 plus adriamycin and cyclophosphamide by intravenous infusion without hydration, repeated every 4 weeks, 2-4 courses. The response rate was 56% (18/32) and 48% (10/21), respectively. There were obviously different response rates in patients with previous chemotherapy (25% and 23% in cp single and combination chemotherapy groups) and without chemotherapy (67% and 88% in single and combination groups). It showed that cp was effective in treatment of ovarian cancers with advantages that gastrointestinal reaction was less severe in cp group than in the group using drugs including cis-platin, and no renal toxicity. However, cp showed more marked myelosuppression and hepatic injury in small number of the patients.
Liu
L Y
LY
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003536:Cystadenocarcinoma / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D003520:Cyclophosphamide; D016190:Carboplatin